JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Cellectis SA (CLLS – Research Report) today and set a price target of $11.00. The company’s shares opened today at $2.46.
Tuerkcan covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, MacroGenics, and Crispr Therapeutics AG. According to TipRanks, Tuerkcan has an average return of -5.7% and a 30.83% success rate on recommended stocks.
Currently, the analyst consensus on Cellectis SA is a Moderate Buy with an average price target of $19.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Cellectis SA’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.35 million and a GAAP net loss of $18.95 million. In comparison, last year the company earned a revenue of $11.18 million and had a GAAP net loss of $39.92 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Read More on CLLS:
- Monthly information on share capital and company voting rights
- Zentalis appoints Carrie Brownstein as CMO
- Cellectis Announces Participation in Four Upcoming Investor Conferences in September
- Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
- Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
